Aclidinium bromide 200 μg bid

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.

CompletedNCT01120093

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2010-05-31End: 2010-08-31Updated: 2017-01-09

Phase 3

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT01001494

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-10-31End: 2010-11-30Updated: 2017-01-04

Related Papers

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials

BMJ Open Respiratory Research2016-12-0118 citations

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.

2016-05-2317 citations

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.

2012-04-0428 citations